Association of activated c-Met with NRAS-mutated human melanomas

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Cutaneous melanomas are classified into BRAF-mutated, NRAS-mutated, and wild-type (wt/wt) genetic subsets.
• Targeted therapies primarily focus on BRAF mutations, leaving NRAS-mutated and wt/wt melanoma with fewer options.
• The c-Met pathway is implicated in melanoma development and may be activated in NRAS-mutated tumors.

Purpose of the Study:

• To investigate the hypothesis that NRAS-mutated melanomas are uniquely sensitive to c-Met pathway inhibition.
• To explore the therapeutic potential of targeting c-Met in specific melanoma genetic subsets.

Main Methods:

• Analysis of primary human melanomas with known BRAF/NRAS genotypes.
• Immunostaining for phosphorylated c-Met and Akt.
• Cell line experiments involving hepatocyte growth factor (HGF) stimulation and N-Ras knockdown via RNA interference.
• Assessment of sensitivity to pharmacologic c-Met inhibition, including proliferation, migration, and apoptosis assays.

Main Results:

• NRAS-mutated and wt/wt melanomas exhibited higher phosphorylated c-Met levels compared to BRAF-mutated tumors.
• NRAS-mutated melanoma cells showed increased sensitivity to c-Met inhibition, affecting proliferation, migration, and apoptosis.
• Knockdown of mutated N-Ras reduced c-Met phosphorylation, while wild-type N-Ras knockdown did not.
• wt/wt melanoma cells also showed sensitivity to c-Met inhibition, though less consistently.

Conclusions:

• c-Met pathway inhibition is a potential therapeutic strategy for NRAS-mutated melanomas.
• This approach may also benefit a subset of wt/wt melanomas.
• Targeting c-Met offers a promising avenue for treating melanoma patients with specific genetic profiles beyond BRAF mutations.